We Don't Chase Headlines, But (Nasdaq: IMNN) Keeps Showing Up On Our Early Radar

Wednesday's profile was cooking early.

Any content you receive is for information purposes only. Always conduct your own research. *Sponsored We Don't Chase Headlines, But (Nasdaq: IMNN) Keeps Showing Up On Our Early Radar *Click Here To Get Our Alerts Faster Via SMS* July 30th Greetings Readers, Wednesday's profile was cooking early. After being brought into focus on Tuesday night after closing at $5.80, it shot to a high of $7.55 one day later. That short term surge resulted in a run of approx. 30%. Then, there's this... For thirty years, the standard of care for newly diagnosed advanced ovarian cancer has remained essentially unchanged. That is not a gap in the market. That is a wall. And Imunon, Inc. (Nasdaq: IMNN) appears to be drilling through it. IMNN is a clinical-stage biopharmaceutical company with a singular focus: deploying a first-in-class DNA-based immunotherapy to confront one of oncology's most treatment-resistant cancers. The company's technology does not follow the usual path of layering another chemotherapy on top of an already-stressed treatment framework. Instead, it introduces a fundamentally different biological approach designed to activate the patient's own immune system against the tumor. The core of that approach is the TheraPlas® nanoparticle platform, a proprietary gene delivery system that carries therapeutic DNA directly to the tumor site without using a viral vector. The lead program, IMNN-001, uses this platform to express interleukin-12 (IL-12), a potent immune-activating cytokine, directly in the abdominal cavity where ovarian tumors typically spread. Earlier IL-12 therapies failed because systemic administration caused severe toxicities. IMNN-001 addresses that problem with localized delivery and a safety profile that Phase 2 data supports. In a randomized 112-patient OVATION 2 study, IMNN-001 added a median of 14.7 months to overall survival compared to standard-of-care chemotherapy alone, a 45.1-month median versus 30.4 months in the control arm. In the subgroup of patients who also received PARP inhibitor maintenance therapy, that survival advantage expanded to 24.2 months. The OVATION 2 data was subsequently published in the peer-reviewed journal Gynecologic Oncology and selected for an oral presentation at the 2025 ASCO Annual Meeting, one of oncology’s most competitive scientific forums. Now the company has moved into Phase 3. The OVATION-3 trial is a 500-patient, randomized registrational study with overall survival as the primary endpoint. In June 2026, the independent Data Monitoring Committee completed a planned interim safety and efficacy review and recommended the trial continue without modification. That is a significant clinical checkpoint, confirming the trial is proceeding as designed and that no safety signals have emerged to warrant concern. Most recently, on July 23rd, 2026, Imunon presented new IMNN-001 data at the inaugural AACR Conference on Drug Discovery and Development in Boston. Company CEO Stacy Lindborg described the selection as "an important recognition of Imunon's platform," while Chief Medical Officer Sebastien Hazard stated the program "establishes a new paradigm for immunotherapy" in this setting. A Deeper Company Dive: Imunon, Inc. (Nasdaq: IMNN) Imunon was built from the former clinical-stage company Celsion Corporation, which rebranded in 2022 to reflect its concentrated focus on DNA-based immunotherapy. At the heart of that focus is the proprietary TheraPlas® platform, a non-viral, nanoparticle delivery system designed to transport therapeutic DNA directly into the tumor microenvironment without the manufacturing challenges or immunogenic risks tied to viral vector approaches. IMNN-001 is a DNA plasmid encoding interleukin-12 (IL-12), a potent immune-activating cytokine, delivered intraperitoneally (directly into the abdominal cavity). Earlier attempts to harness IL-12 systemically failed because the doses needed for therapeutic effect caused severe toxicity. Imunon’s approach sidesteps that entirely. By delivering IL-12 locally through TheraPlas®, the company’s treatment activates the immune system at the tumor site, converting an immunologically “cold” tumor into an active, immune-engaged environment, while keeping systemic exposure to a minimum. In OVATION 2, zero serious immune-related adverse events were observed. The pipeline extends well beyond ovarian cancer. The same TheraPlas® platform is being positioned for colorectal cancer, pancreatic cancer, and glioblastoma. IMNN-001 holds FDA Fast Track designation and Orphan Drug designation in both the United States and the European Union, a regulatory package that may support an accelerated path toward a potential BLA submission. The Company's Product Pipeline 7 Potential Catalysts Put (Nasdaq: IMNN) Front And Center #1. Phase 3 OVATION-3 Enrollment Is Running Ahead Of Schedule: Clinical progress with IMNN has outpaced initial projections, with enrollment tracking ahead of plan and 50% enrollment now targeted for Q1 2028, according to the company's Q1 2026 update. #2. Independent Safety Committee Cleared The Trial In June: The trial's independent Data Monitoring Committee reviewed OVATION-3 in June 2026 and recommended continuation without modification, a major regulatory checkpoint that validates the safety and trial design integrity of the IMNN Phase 3 program. #3. FDA Alignment On Protocol Removes Key Regulatory Uncertainty: The FDA has confirmed alignment with IMNN on the OVATION-3 protocol and confirmed the pathway to BLA filing, a critical regulatory milestone that meaningfully reduces uncertainty around the approval process. #4. An Analyst $25 Target Points To Potential Quadruple-Digit Upside: An analyst at Zacks Small Cap Research has pegged a $25 target on IMNN. From Wednesday's close, that target hints at a potential 1,400+% upside. #5. Concentrated Float Could Amplify The Potential For Heightened Volatility: With an estimated float of approximately 3.81Mn shares, the potential for heightened volatility may be significant on a daily basis. #6. AACR Conference Selection Adds Peer Scientific Validation: Imunon was selected to present IMNN data at the inaugural AACR Conference on Drug Discovery and Development in Boston on July 23, 2026, adding an additional layer of peer validation to the TheraPlas® platform and its clinical results. #7. Two Planned Interim Analyses Create Near-Term Data Windows: OVATION-3 includes two pre-planned interim analyses for potential early stopping and BLA submission, meaning IMNN doesn't necessarily need to wait until full trial completion for the first major data readout that could validate the program. Closing Thoughts Imunon, Inc. (Nasdaq: IMNN) is a clinical-stage name carrying a development thesis that is difficult to overlook. Thirty years without a meaningful advance in frontline ovarian cancer treatment is the kind of gap that defines entire careers in the medical space when someone finally closes it. The Phase 2 data is public, peer-reviewed, and published. The Phase 3 trial is actively enrolling, tracking ahead of schedule, and backed by FDA alignment. The DMC just cleared it in June. The company presented at AACR this month. The body of evidence is building, the scientific community is paying attention, and the potential catalysts ahead are real and time-bound. We're kicking-off coverage on Imunon, Inc. (Nasdaq: IMNN). Be on the lookout for updates coming out soon. Talk again shortly. Sincerely, Kai Parker StockWireNews More Sources: IMNN Website IMNN Presentation (Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.) *StockWireNews.com (“StockWireNews” or “SWN” ) is owned by SWN Media LLC, a single member limited liability company. Data is provided from third-party sources and SWN is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile SWN brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors. Pursuant to an agreement between SWN Media LLC and TD Media LLC, SWN Media LLC has been hired for a period beginning on 07/29/2026 and ending on 07/30/2026 to publicly disseminate information about (IMNN:US) via digital communications. Under this agreement, TD Media LLC has paid SWN Media LLC seventeen thousand five hundred USD ("Funds"). These Funds were part of the forty thousand USD funds that TD Media LLC received from a third party named LFG Equities Corp. who did not receive the Funds directly or indirectly from the Issuer and does not own st-ock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices. Neither SWN Media LLC, TD Media LLC and their member own shares of (IMNN:US). Please see important disclosure information here: https://stockwirenews.com/disclosure/imnn-gfvdv/#details

SWN Media | 4808 NW 2nd Ave Unit #388 | Boca Raton, FL 33431 US Unsubscribe | Update Profile | Constant Contact Data Notice